HighTower Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

HighTower Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-71,982	Closed	-$302K	–	3812
2023 Q1	$302K	Hold	71,982	–	–	﹤0.01%	2446
2022 Q4	$433K	Buy	71,982 +1,500	+2%	+$8.19K	﹤0.01%	2221
2022 Q3	$411K	Hold	70,482	–	–	﹤0.01%	2147
2022 Q2	$421K	Buy	+70,482	New	+$361K	﹤0.01%	2153

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

HighTower Advisors's CTIC Position: Q2 2023 in Review

HighTower Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 71,982 shares — an estimated $302K sold.

HighTower Advisors first reported a position in CTIC in Q2 2022 and held it in 4 quarters. The position peaked at $433K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

HighTower Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
HighTower Advisors sold 71,982 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $302K.
HighTower Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 4 quarters.
HighTower Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $433K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on HighTower Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.